` 145020 (Hugel Inc) vs KOSPI 200 Comparison - Alpha Spread

145020
vs
KOSPI 200

Over the past 12 months, has significantly outperformed KOSPI 200, delivering a return of 72% compared to the KOSPI 200's 6% drop.

Stocks Performance
145020 vs KOSPI 200

Loading

Performance Gap
145020 vs KOSPI 200

Loading
145020
KOSPI 200
Difference

Performance By Year
145020 vs KOSPI 200

Loading
145020
KOSPI 200
Add Stock

Competitors Performance
Hugel Inc vs Peers

KOSPI 200
145020
ABBV
AMGN
GILD
VRTX
Add Stock

Hugel Inc
Glance View

Market Cap
4.2T KRW
Industry
Biotechnology

In the bustling landscape of the global biopharmaceutical market, Hugel Inc. stands out as a formidable player rooted in the dynamic world of aesthetics and medical treatments. Established in South Korea, Hugel Inc. embarked on its journey with a focus on producing botulinum toxin products, a niche that has rapidly expanded due to a surge in demand for non-surgical cosmetic procedures. The company navigated early challenges with innovative prowess, crafting a strong reputation for high-quality products that cater to a global clientele. The ethos of innovation and safety permeates its operations, enabling Hugel to diversify its portfolio and steadily gain traction in international markets, including significant footprints in Asia, Europe, and Latin America. Through a network of strategic partnerships and a robust distribution channel, Hugel not only pioneered advancements in cosmetic treatments but also cemented its status as a key contributor to the evolving aesthetics industry. The company's revenue model hinges upon the development, production, and distribution of its botulinum toxin and hyaluronic acid-based products. By focusing on research and development, Hugel enhances its capacity to innovate, delivering cutting-edge solutions that meet the rising demands of beauty-conscious consumers. Its business strategy also extends to therapeutics, exploring potential applications of its core products to address various medical conditions. Hugel's financial growth is propelled by the continuous expansion into new geographical territories and the gradual introduction of new, clinically-researched products. As the company continues to navigate the intricate regulatory landscapes of the pharmaceutical industry, it maintains an unwavering commitment to quality, ensuring that each product meets rigorous safety standards while catering to the evolving desires of its diverse customer base worldwide.

Intrinsic Value
287 792.06 KRW
Overvaluation 13%
Intrinsic Value
Price
H
Back to Top